Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have earned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $7.20.

Several research analysts have commented on the company. Royal Bank Of Canada cut their target price on Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating on the stock in a report on Thursday, December 18th. Stephens raised their price objective on Pyxis Oncology from $5.00 to $8.00 and gave the stock an “overweight” rating in a research report on Monday, November 24th. Zacks Research lowered Pyxis Oncology from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th. Wall Street Zen downgraded shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Finally, Guggenheim raised their price target on shares of Pyxis Oncology from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th.

Hedge Funds Weigh In On Pyxis Oncology

Hedge funds and other institutional investors have recently bought and sold shares of the company. Catalyst Funds Management Pty Ltd acquired a new stake in Pyxis Oncology during the 2nd quarter worth about $26,000. Kingstone Capital Partners Texas LLC bought a new stake in shares of Pyxis Oncology during the 2nd quarter valued at about $37,000. XTX Topco Ltd bought a new stake in shares of Pyxis Oncology during the 2nd quarter valued at about $40,000. Velan Capital Investment Management LP acquired a new stake in Pyxis Oncology during the second quarter worth approximately $44,000. Finally, Persistent Asset Partners Ltd bought a new stake in Pyxis Oncology in the third quarter worth approximately $77,000. Institutional investors and hedge funds own 39.09% of the company’s stock.

Pyxis Oncology Price Performance

PYXS opened at $1.45 on Friday. Pyxis Oncology has a fifty-two week low of $0.83 and a fifty-two week high of $5.55. The company’s 50 day moving average price is $3.39 and its two-hundred day moving average price is $2.37. The firm has a market capitalization of $90.28 million, a price-to-earnings ratio of -0.91 and a beta of 1.44.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.01. As a group, equities research analysts predict that Pyxis Oncology will post -1.04 EPS for the current year.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.